<DOC>
	<DOCNO>NCT02485925</DOCNO>
	<brief_summary>This prospective effectiveness safety assessment study device radiofrequency ( RF ) ablation treatment patient drug refractory symptomatic atrial fibrillation .</brief_summary>
	<brief_title>SMART China , A Multi-center Clinical Registry Study</brief_title>
	<detailed_description>The purpose study assess effectiveness safety THERMOCOOL® SMARTTOUCH™ catheter treatment drug refractory symptomatic paroxysmal atrial fibrillation ( PAF ) undergo CPVI .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Age 18 year old 2 . Failure least one antiarrhythmic drug ( AAD ) AF ( class I III , AV nodal block agent beta blocker calcium channel blocker ) evidence recurrent symptomatic AF , intolerance AAD 3 . Patients paroxysmal AF eligible catheter ablation 4 . Patients symptomatic PAF least one document AF episode six ( 6 ) month prior enrollment . Documentation may include limited electrocardiogram ( ECG ) , Holter monitor ( HM ) transtelephonic monitor ( TTM ) 5 . Able willing comply pre , post followup test requirement 6 . Be able sign IRB/ECapproved inform consent form 1 . AF secondary electrolyte imbalance , thyroid disease , reversible noncardiac cause 2 . Previous surgical catheter ablation AF 3 . Any PCI , cardiac surgery , valvular cardiac surgical percutaneous procedure ( e.g. , ventriculotomy , atriotomy , valve repart replacement presence prosthetic valve ) within past 2 month . 4 . Any carotid stenting endarterectomy . 5 . Coronary artery bypass graft ( CABG ) procedure within last 180 day ( 6 month ) 6 . AF episodes lasting longer 7 day terminate via cardioversion 7 . Documented leave atrial thrombus image 8 . Uncontrolled heart Failure New York Heart Association ( NYHA ) class III IV 9 . Myocardial Infarction within previous 60 day ( 2 month ) 10 . Documented thromboembolic event ( include TIA ) within past 12 month 11 . Rheumatic heart disease 12 . Awaiting cardiac transplantation cardiac surgery within next 365 day ( 12 month ) 13 . Significant pulmonary disease , ( e.g. , restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . 14 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study 15 . Active illness active systemic infection sepsis 16 . Diagnosed atrial myxoma 17 . Unstable angina within past 60 day ( 2 month ) 18 . History blood clot bleed abnormality 19 . Life expectancy le 365 day ( 12 month ) 20 . Hypertrophic obstructive cardiomyopathy 21 . Presence implant ICD 22 . Contraindication anticoagulation 23 . Contraindication isoproterenol 24 . Presence intramural thrombus , tumor abnormality precludes catheter introduction manipulation 25 . Women pregnant and/or breast feed 26 . Presence condition precludes vascular access . 27 . Patients present contraindication study catheter ( ) , indicate respective Instructions For Use 28 . Enrollment investigational study evaluate another device , biologic , drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Interventional</keyword>
	<keyword>Radiofrequency ablation</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Catheter ablation</keyword>
</DOC>